oleylamide and Skin-Neoplasms

oleylamide has been researched along with Skin-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for oleylamide and Skin-Neoplasms

ArticleYear
A derivative of oleamide potently inhibits the spontaneous metastasis of mouse melanoma BL6 cells.
    Carcinogenesis, 2004, Volume: 25, Issue:10

    We reported previously that the abnormally augmented expression of connexin 26 (Cx26) is responsible for the enhanced spontaneous metastasis of mouse BL6 melanoma cells, and that the exogenous expression of a dominant negative form of Cx26 inhibits the spontaneous metastasis of BL6. Here we show that daily intraperitoneal (i.p.) injections of oleamide, a sleep-inducing lipid hormone, weakly inhibited the spontaneous metastasis of BL6 cells. To obtain a more effective reagent, 19 oleamide derivatives were chemically synthesized and tested for their ability to inhibit the gap junction-mediated intercellular communications (GJIC) that are formed between HeLa cells by the ectopic expression of Cx26 or Cx43. One of these, denoted metastasis inhibitor-18 (MI-18), inhibited the GJIC formed by Cx26 as well as oleamide but unlike oleamide, which is a non-selective inhibitor of connexin, it did not inhibit the GJIC formed by Cx43. Daily i.p. injections of MI-18 potently blocked the spontaneous metastasis of BL6 cells down to 15% of that in the untreated control mice. MI-18 was safe because even after >7 weeks of daily injections, the survival rate of the mice was 93%. We propose that MI-18 may serve as a novel and clinically important prototype of a potent inhibitor of spontaneous metastasis.

    Topics: Animals; Cell Communication; Connexin 26; Connexin 43; Connexins; Gap Junctions; HeLa Cells; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Melanoma, Experimental; Mice; Oleic Acids; Skin Neoplasms; Survival Rate; Transfection

2004